RecruitingNot ApplicableNCT05856877

Central Insulin Sensitivity in Individuals With Type 2 Diabetes (T2D) and at Risk for Developing T2D

Zentrale Insulinsensitivität Bei Personen Mit Typ-2-Diabetes Sowie Bei Personen Mit erhöhtem Risiko für Die Entwicklung Von Typ-2-Diabetes


Sponsor

University Hospital Tuebingen

Enrollment

180 participants

Start Date

May 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Beside well described peripheral effects, insulin can also affect the human central nervous system. Centrally acting insulin seems to have an influence e.g. on whole-body metabolism and food intake. Targeting insulin receptors in the central nervous system can modulate peripheral insulin sensitivity as well as pancreatic insulin secretion. In humans, the effect of insulin can be measured in different brain areas as estimate of central nervous insulin sensitivity. Reduced central nervous insulin sensitivity, called "central insulin resistance," has been associated, for example, with obesity, unfavorable body fat distribution, and impaired cognitive functionality. Recently novel subtypes and risk clusters of diabetes and prediabetes have been identified. In this study the investigators want to investigate and compare central nervous insulin sensitivity as well as cognitive function in the different diabetes and prediabetes risk clusters.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how the brain responds to insulin (a hormone that regulates blood sugar) in people with Type 2 diabetes, those at risk for it (prediabetes), and healthy individuals. It aims to understand whether insulin resistance in the brain contributes to the development of Type 2 diabetes. **You may be eligible if...** - You have been diagnosed with Type 2 diabetes within the past 10 years, OR - You have prediabetes (slightly elevated blood sugar), a family history of Type 2 diabetes, recent gestational diabetes, or a BMI over 27, OR - You have no diabetes and no risk factors (as a healthy control participant) **You may NOT be eligible if...** - You have serious health conditions that would make the study tests unsafe - You have conditions affecting hormone levels or blood sugar regulation beyond Type 2 diabetes Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHuman nasal insulin

single dose of 160 U of human insulin as nasal spray

OTHERPlacebo

Single dose of placebo solution as nasal spray


Locations(1)

University Hospital Tübingen

Tübingen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05856877


Related Trials